☰

Daniel Hoyer, Ph.D. - Publications

Affiliations: 
2014 Classics New York University, New York, NY, United States 
Area:
Classical Studies, History Economics, African History
Tree Info Similar researchers PubMed Report error

243 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Frontiers in Cellular Neuroscience. 16: 812359. PMID 35496914 DOI: 10.3389/fncel.2022.812359  0.324
2021 Coleman P, de Lecea L, Gotter A, Hagan J, Hoyer D, Kilduff T, Kukkonen JP, Porter R, Renger J, Siegel JM, Sutcliffe G, Upton N, Winrow CJ. Orexin receptors in GtoPdb v.2021.3. Iuphar/Bps Guide to Pharmacology Cite. 2021. PMID 34927075 DOI: 10.2218/gtopdb/f51/2021.3  0.331
2021 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, ... ... Hoyer D, et al. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews. 73: 310-520. PMID 33370241 DOI: 10.1124/pr.118.015552  0.374
2020 Hoyer D, Professorial Fellow H, Adjunct. Targeting the 5-HT system: Potential side effects. Neuropharmacology. 108233. PMID 32805212 DOI: 10.1016/J.Neuropharm.2020.108233  0.41
2020 Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews. 53: 101332. PMID 32505969 DOI: 10.1016/J.Smrv.2020.101332  0.303
2020 Vilaró MT, Cortés R, Mengod G, Hoyer D. Distribution of 5-HT receptors in the central nervous system: an update Handbook of Behavioral Neuroscience. 31: 121-146. DOI: 10.1016/B978-0-444-64125-0.00006-2  0.471
2018 Schneider EK, McQuade RM, Carbone VC, Reyes-Ortega F, Wilson JW, Button B, Saito A, Poole DP, Hoyer D, Li J, Velkov T. The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites. Erj Open Research. 4. PMID 29560360 DOI: 10.1183/23120541.00127-2017  0.302
2018 Hoyer D, Jacobson L. Lemborexant. Dual orexin receptor antagonist, Treatment of insomnia Drugs of the Future. 43: 715. DOI: 10.1358/Dof.2018.043.10.2828699  0.433
2017 Hoyer D. 5-HT Receptor Nomenclature: Naming names, does it matter? A tribute to Maurice Rapport. Acs Chemical Neuroscience. PMID 28269984 DOI: 10.1021/Acschemneuro.7B00011  0.475
2017 Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology. PMID 28265714 DOI: 10.1007/S00213-017-4545-5  0.383
2017 Jacobson LH, Hoyer D, Fehlmann D, Bettler B, Kaupmann K, Cryan JF. Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms. Psychopharmacology. PMID 28070618 DOI: 10.1007/S00213-016-4521-5  0.417
2016 Andreetta F, Carboni L, Grafton G, Jeggo R, Whyment AD, van den Top M, Hoyer D, Spanswick D, Barnes NM. Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo. British Journal of Pharmacology. PMID 26773257 DOI: 10.1111/Bph.13432  0.481
2015 Behnke D, Cotesta S, Hintermann S, Fendt M, Gee CE, Jacobson LH, Laue G, Meyer A, Wagner T, Badiger S, Chaudhari V, Chebrolu M, Pandit C, Hoyer D, Betschart C. Discovery of 1H-pyrazolo[3,4-b]pyridines as potent dual orexin receptor antagonists (DORAs). Bioorganic & Medicinal Chemistry Letters. PMID 26522950 DOI: 10.1016/J.Bmcl.2015.10.055  0.385
2015 Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T, Lopez Lopez C. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. British Journal of Pharmacology. 172: 1292-304. PMID 25363835 DOI: 10.1111/Bph.13001  0.414
2014 Lewis I, Schmid HA, Kneuer R, Hoyer D, Silva AP, Weckbecker G, Bruns C, Pless J. SOM230: A new therapeutic modality for cushing's disease Chimia. 68: 483-484. PMID 25437387 DOI: 10.2533/Chimia.2014.483  0.413
2014 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology. 7: 711-30. PMID 25318834 DOI: 10.1586/17512433.2014.966813  0.307
2013 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, ... Hoyer D, et al. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Frontiers in Neuroscience. 7: 230. PMID 24376396 DOI: 10.3389/Fnins.2013.00230  0.49
2013 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Neuropeptides. 47: 477-88. PMID 24215799 DOI: 10.1016/J.Npep.2013.10.009  0.375
2013 O'Connor RM, Thakker DR, Schmutz M, van der Putten H, Hoyer D, Flor PJ, Cryan JF. Adult siRNA-induced knockdown of mGlu7 receptors reduces anxiety in the mouse. Neuropharmacology. 72: 66-73. PMID 23603202 DOI: 10.1016/J.Neuropharm.2013.03.028  0.436
2012 Hoyer D, Bartfai T. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach. Chemistry & Biodiversity. 9: 2367-87. PMID 23161624 DOI: 10.1002/Cbdv.201200288  0.467
2012 Nilsson A, Stroth N, Zhang X, Qi H, Fälth M, Sköld K, Hoyer D, Andrén PE, Svenningsson P. Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology. 62: 347-57. PMID 21856315 DOI: 10.1016/J.Neuropharm.2011.08.004  0.363
2011 Hoyer D. 5-HT-7 receptor Xpharm: the Comprehensive Pharmacology Reference. 1-1. DOI: 10.1016/B978-008055232-3.63761-4  0.331
2011 Hoyer D. 5-HT-6 receptor Xpharm: the Comprehensive Pharmacology Reference. 1-1. DOI: 10.1016/B978-008055232-3.63760-2  0.331
2011 Hoyer D. 5-HT-4 receptor Xpharm: the Comprehensive Pharmacology Reference. 1-16. DOI: 10.1016/B978-008055232-3.63759-6  0.359
2011 Hoyer D. 5-HT-5 receptors Xpharm: the Comprehensive Pharmacology Reference. 1-1. DOI: 10.1016/B978-008055232-3.63754-7  0.331
2011 Hoyer D. 5-ht-3b receptor Xpharm: the Comprehensive Pharmacology Reference. 1-12. DOI: 10.1016/B978-008055232-3.63723-7  0.332
2011 Hoyer D. 5-ht-3a receptor Xpharm: the Comprehensive Pharmacology Reference. 1-15. DOI: 10.1016/B978-008055232-3.63722-5  0.329
2011 Hoyer D. 5-HT-3 receptor Xpharm: the Comprehensive Pharmacology Reference. 1-7. DOI: 10.1016/B978-008055232-3.60366-6  0.355
2011 Hoyer D. SST-5 somatostatin receptor Xpharm: the Comprehensive Pharmacology Reference. 1-13. DOI: 10.1016/B978-008055232-3.60348-4  0.36
2011 Hoyer D. SST-4 somatostatin receptor Xpharm: the Comprehensive Pharmacology Reference. 1-12. DOI: 10.1016/B978-008055232-3.60347-2  0.36
2011 Hoyer D. SST-3 somatostatin receptor Xpharm: the Comprehensive Pharmacology Reference. 1-12. DOI: 10.1016/B978-008055232-3.60346-0  0.344
2011 Hoyer D. SST-2 somatostatin receptor Xpharm: the Comprehensive Pharmacology Reference. 1-15. DOI: 10.1016/B978-008055232-3.60345-9  0.356
2011 Hoyer D. 5-HT-2C receptor Xpharm: the Comprehensive Pharmacology Reference. 1-11. DOI: 10.1016/B978-008055232-3.60133-3  0.372
2011 Hoyer D. 5-HT-2B receptor Xpharm: the Comprehensive Pharmacology Reference. 1-9. DOI: 10.1016/B978-008055232-3.60132-1  0.349
2011 Hoyer D. 5-HT-2 receptors Xpharm: the Comprehensive Pharmacology Reference. 1-4. DOI: 10.1016/B978-008055232-3.60130-8  0.331
2011 Hoyer D. 5-HT-1F receptor Xpharm: the Comprehensive Pharmacology Reference. 1-8. DOI: 10.1016/B978-008055232-3.60129-1  0.301
2011 Hoyer D. 5-HT-1E receptor Xpharm: the Comprehensive Pharmacology Reference. 1-8. DOI: 10.1016/B978-008055232-3.60128-X  0.32
2011 Hoyer D. 5-HT-1B receptor Xpharm: the Comprehensive Pharmacology Reference. 1-15. DOI: 10.1016/B978-008055232-3.60125-4  0.331
2011 Hoyer D. 5-HT-1A receptor Xpharm: the Comprehensive Pharmacology Reference. 1-10. DOI: 10.1016/B978-008055232-3.60124-2  0.32
2011 Hoyer D. 5-HT-1 receptors Xpharm: the Comprehensive Pharmacology Reference. 1-3. DOI: 10.1016/B978-008055232-3.60123-0  0.327
2011 Hoyer D. 5-hydroxytryptamine receptors Xpharm: the Comprehensive Pharmacology Reference. 1-7. DOI: 10.1016/B978-008055232-3.60122-9  0.358
2010 Hoyer D. Neuropeptide receptor positive allosteric modulation in epilepsy: galanin modulation revealed. Proceedings of the National Academy of Sciences of the United States of America. 107: 14943-4. PMID 20713719 DOI: 10.1073/Pnas.1010365107  0.384
2010 Semenova S, Hoyer D, Geyer MA, Markou A. Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats. Neuropeptides. 44: 421-9. PMID 20537385 DOI: 10.1016/J.Npep.2010.04.008  0.316
2010 Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience. 167: 1160-7. PMID 20303391 DOI: 10.1016/J.Neuroscience.2010.03.022  0.419
2010 Troxler T, Hurth K, Schuh KH, Schoeffter P, Langenegger D, Enz A, Hoyer D. Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst(3) receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20: 1728-34. PMID 20137944 DOI: 10.1016/J.Bmcl.2010.01.063  0.384
2010 De Bundel D, Aourz N, Kiagiadaki F, Clinckers R, Hoyer D, Kastellakis A, Michotte Y, Thermos K, Smolders I. Hippocampal sst(1) receptors are autoreceptors and do not affect seizures in rats. Neuroreport. 21: 254-8. PMID 20134357 DOI: 10.1097/Wnr.0B013E3283353A64  0.385
2010 Vranesic IT, Hoyer D. Assessing allosteric ligand-receptor interactions G Protein-Coupled Receptors: Structure, Signaling, and Physiology. 247-269. DOI: 10.1017/CBO9780511760334.014  0.349
2010 Mengod G, Cortés R, Vilaró MT, Hoyer D. Distribution of 5-HT Receptors in the Central Nervous System Handbook of Behavioral Neuroscience. 21: 123-138. DOI: 10.1016/S1569-7339(10)70074-6  0.487
2010 Hoyer D, Bartfai T. Neuropeptide Receptors - Drug Development Encyclopedia of Neuroscience. 801-810. DOI: 10.1016/B978-008045046-9.01451-0  0.316
2009 Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C. Somatostatin, Alzheimer's disease and cognition: an old story coming of age? Progress in Neurobiology. 89: 153-61. PMID 19595735 DOI: 10.1016/J.Pneurobio.2009.07.002  0.329
2009 Erchegyi J, Cescato R, Grace CR, Waser B, Piccand V, Hoyer D, Riek R, Rivier JE, Reubi JC. Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues. Journal of Medicinal Chemistry. 52: 2733-46. PMID 19351180 DOI: 10.1021/Jm801314F  0.459
2009 Troxler T, Hurth K, Mattes H, Prashad M, Schoeffter P, Langenegger D, Enz A, Hoyer D. Discovery of novel non-peptidic beta-alanine piperazine amide derivatives and their optimization to achiral, easily accessible, potent and selective somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 19: 1305-9. PMID 19208473 DOI: 10.1016/J.Bmcl.2009.01.072  0.419
2009 Pallis E, Vasilaki A, Fehlmann D, Kastellakis A, Hoyer D, Spyraki C, Thermos K. Antidepressants influence somatostatin levels and receptor pharmacology in brain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 952-63. PMID 18800063 DOI: 10.1038/Npp.2008.133  0.381
2009 Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. 56: 254-63. PMID 18793655 DOI: 10.1016/J.Neuropharm.2008.08.025  0.325
2009 Seebach D, Widmer H, Capone S, Ernst R, Bremi T, Kieltsch I, Togni A, Monna D, Langenegger D, Hoyer D. NMR-solution structures and affinities for the human somatostatin G-protein-coupled receptors hsst 1-5 of CF 3 derivatives of Sandostatin® (octreotide) Helvetica Chimica Acta. 92: 2577-2586. DOI: 10.1002/Hlca.200900279  0.334
2008 Gardiner J, Langenegger D, Hoyer D, Beck AK, Mathad RI, Seebach D. The enantiomer of octreotate binds to all five somatostatin receptors with almost equal micromolar affinity--a comparison with SANDOSTATIN. Chemistry & Biodiversity. 5: 1213-24. PMID 18649310 DOI: 10.1002/Cbdv.200890110  0.455
2008 Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behavioural Brain Research. 195: 198-213. PMID 18571247 DOI: 10.1016/J.Bbr.2008.03.020  0.405
2008 Siehler S, Nunn C, Hannon J, Feuerbach D, Hoyer D. Pharmacological profile of somatostatin and cortistatin receptors. Molecular and Cellular Endocrinology. 286: 26-34. PMID 18243519 DOI: 10.1016/J.Mce.2007.12.007  0.498
2008 Troxler T, Enz A, Hoyer D, Langenegger D, Neumann P, Pfäffli P, Schoeffter P, Hurth K. Ergoline derivatives as highly potent and selective antagonists at the somatostatin sst 1 receptor. Bioorganic & Medicinal Chemistry Letters. 18: 979-82. PMID 18162395 DOI: 10.1016/J.Bmcl.2007.12.030  0.442
2008 Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacology & Therapeutics. 117: 77-93. PMID 17961662 DOI: 10.1016/J.Pharmthera.2007.08.005  0.311
2008 Fendt M, Schmid S, Thakker DR, Jacobson LH, Yamamoto R, Mitsukawa K, Maier R, Natt F, Hüsken D, Kelly PH, McAllister KH, Hoyer D, van der Putten H, Cryan JF, Flor PJ. mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Molecular Psychiatry. 13: 970-9. PMID 17712315 DOI: 10.1038/Sj.Mp.4002073  0.3
2008 Seebach D, Dubost E, Mathad RI, Jaun B, Limbach M, Löweneck M, Flögel O, Gardiner J, Capone S, Beck AK, Widmer H, Langenegger D, Monna D, Hoyer D. New open-chain and cyclic tetrapeptides, consisting of α-, β2-, and β3-amino-acid residues, as somatostatin mimics - A survey Helvetica Chimica Acta. 91: 1736-1786. DOI: 10.1002/Hlca.200890190  0.331
2007 Hurth K, Enz A, Floersheim P, Gentsch C, Hoyer D, Langenegger D, Neumann P, Pfäffli P, Sorg D, Swoboda R, Vassout A, Troxler T. SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17: 3988-91. PMID 17512199 DOI: 10.1016/J.Bmcl.2007.04.078  0.47
2007 Troxler T, Hoyer D, Langenegger D, Neumann P, Pfäffli P, Schoeffter P, Sorg D, Swoboda R, Hurth K. Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 17: 3983-7. PMID 17507221 DOI: 10.1016/J.Bmcl.2007.04.086  0.456
2007 Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist. Neuroscience Letters. 416: 61-5. PMID 17314009 DOI: 10.1016/J.Neulet.2007.01.045  0.421
2007 Hintermann S, Vranesic I, Allgeier H, Brülisauer A, Hoyer D, Lemaire M, Moenius T, Urwyler S, Whitebread S, Gasparini F, Auberson YP. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorganic & Medicinal Chemistry. 15: 903-14. PMID 17110115 DOI: 10.1016/J.Bmc.2006.10.038  0.414
2007 Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, Bilbe G, Hoyer D, Bartfai T. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Molecular Psychiatry. 12: 167-89. PMID 17033635 DOI: 10.1038/Sj.Mp.4001897  0.323
2006 Mastrodimou N, Vasilaki A, Papadioti A, Low MJ, Hoyer D, Thermos K. Somatostatin receptors in wildtype and somatostatin deficient mice and their involvement in nitric oxide physiology in the retina. Neuropeptides. 40: 365-73. PMID 17010429 DOI: 10.1016/J.Npep.2006.07.002  0.393
2006 Cammalleri M, Cervia D, Dal Monte M, Martini D, Langenegger D, Fehlmann D, Feuerbach D, Pavan B, Hoyer D, Bagnoli P. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. The European Journal of Neuroscience. 23: 2404-22. PMID 16706848 DOI: 10.1111/J.1460-9568.2006.04770.X  0.345
2006 Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, Waldmeier P, Kaupmann K, Pévet P, Bettler B. Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice. Journal of Neurochemistry. 97: 979-91. PMID 16606363 DOI: 10.1111/J.1471-4159.2006.03806.X  0.335
2006 Thermos K, Bagnoli P, Epelbaum J, Hoyer D. The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina? Pharmacology & Therapeutics. 110: 455-64. PMID 16274747 DOI: 10.1016/J.Pharmthera.2005.09.003  0.487
2005 Thakker DR, Natt F, Hüsken D, van der Putten H, Maier R, Hoyer D, Cryan JF. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Molecular Psychiatry. 10: 782-9, 714. PMID 15940298 DOI: 10.1038/Sj.Mp.4001687  0.341
2005 Cervia D, Langenegger D, Schuepbach E, Cammalleri M, Schoeffter P, Schmid HA, Bagnoli P, Hoyer D. Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology. 48: 881-93. PMID 15829258 DOI: 10.1016/J.Neuropharm.2004.12.019  0.452
2005 van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. American Journal of Physiology. Endocrinology and Metabolism. 289: E278-87. PMID 15769796 DOI: 10.1152/Ajpendo.00004.2005  0.418
2005 Siehler S, Nunn C, Zupanc GK, Hoyer D. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures. Autonomic & Autacoid Pharmacology. 25: 1-16. PMID 15659149 DOI: 10.1111/J.1474-8673.2004.00325.X  0.489
2005 Erchegyi J, Hoeger CA, Low W, Hoyer D, Waser B, Eltschinger V, Schaer JC, Cescato R, Reubi JC, Rivier JE. Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. Journal of Medicinal Chemistry. 48: 507-14. PMID 15658864 DOI: 10.1021/Jm049520L  0.339
2005 Markou A, Harrison AA, Chevrette J, Hoyer D. Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats. Psychopharmacology. 178: 133-42. PMID 15452682 DOI: 10.1007/S00213-004-2008-2  0.325
2004 Cammalleri M, Cervia D, Langenegger D, Liu Y, Dal Monte M, Hoyer D, Bagnoli P. Somatostatin receptors differentially affect spontaneous epileptiform activity in mouse hippocampal slices. The European Journal of Neuroscience. 20: 2711-21. PMID 15548214 DOI: 10.1111/J.1460-9568.2004.03741.X  0.323
2004 Vasilaki A, Papasava D, Hoyer D, Thermos K. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat. Neuropharmacology. 47: 612-8. PMID 15380378 DOI: 10.1016/J.Neuropharm.2004.06.008  0.405
2004 Rodgers RJ, Gentsch C, Hoyer D, Bryant E, Green AJ, Kolokotroni KZ, Martin JL. The NK1 receptor antagonist NKP608 lacks anxiolytic-like activity in Swiss-Webster mice exposed to the elevated plus-maze. Behavioural Brain Research. 154: 183-192. PMID 15302124 DOI: 10.1016/J.Bbr.2004.02.005  0.412
2004 Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K, Neumann P, Troxler T, Pfaeffli P. SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neuroscience Letters. 361: 132-5. PMID 15135911 DOI: 10.1016/J.Neulet.2004.02.017  0.477
2004 Vasilaki A, Papadaki T, Notas G, Kolios G, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouroumalis E, Pallikaris I, Thermos K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. Investigative Ophthalmology & Visual Science. 45: 1499-506. PMID 15111608 DOI: 10.1167/Iovs.03-0835  0.335
2004 Nunn C, Cervia D, Langenegger D, Tenaillon L, Bouhelal R, Hoyer D. Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells. British Journal of Pharmacology. 142: 150-60. PMID 15037513 DOI: 10.1038/Sj.Bjp.0705735  0.371
2003 Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews. Drug Discovery. 2: 999-1017. PMID 14654798 DOI: 10.1038/Nrd1255  0.343
2003 Dal Monte M, Petrucci C, Vasilaki A, Cervia D, Grouselle D, Epelbaum J, Kreienkamp HJ, Richter D, Hoyer D, Bagnoli P. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology. 45: 1080-92. PMID 14614951 DOI: 10.1016/S0028-3908(03)00296-X  0.445
2003 Cervia D, Fehlmann D, Hoyer D. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs. Naunyn-Schmiedeberg's Archives of Pharmacology. 367: 578-87. PMID 12750875 DOI: 10.1007/S00210-003-0752-1  0.429
2003 Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. British Journal of Pharmacology. 139: 109-21. PMID 12746229 DOI: 10.1038/Sj.Bjp.0705235  0.51
2003 Nunn C, Langenegger D, Hurth K, Schmidt K, Fehlmann D, Hoyer D. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists. European Journal of Pharmacology. 465: 211-8. PMID 12681432 DOI: 10.1016/S0014-2999(03)01482-1  0.482
2003 Cervia D, Zizzari P, Pavan B, Schuepbach E, Langenegger D, Hoyer D, Biondi C, Epelbaum J, Bagnoli P. Biological activity of somatostatin receptors in GC rat tumour somatotrophs: Evidence with sst1-sst5 receptor-selective nonpeptidyl agonists Neuropharmacology. 44: 672-685. PMID 12668053 DOI: 10.1016/S0028-3908(03)00031-5  0.476
2003 Nunn C, Schoeffter P, Langenegger D, Hoyer D. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806. Naunyn-Schmiedeberg's Archives of Pharmacology. 367: 1-9. PMID 12616335 DOI: 10.1007/S00210-002-0656-5  0.506
2003 Seebach D, Schaeffer L, Brenner M, Hoyer D. Design and synthesis of gamma-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. Angewandte Chemie (International Ed. in English). 42: 776-8. PMID 12596197 DOI: 10.1002/Anie.200390205  0.4
2003 Nunn C, Rueping M, Langenegger D, Schuepbach E, Kimmerlin T, Micuch P, Hurth K, Seebach D, Hoyer D. Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 367: 95-103. PMID 12595949 DOI: 10.1007/S00210-002-0673-4  0.397
2002 Moneta D, Richichi C, Aliprandi M, Dournaud P, Dutar P, Billard JM, Carlo AS, Viollet C, Hannon JP, Fehlmann D, Nunn C, Hoyer D, Epelbaum J, Vezzani A. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. The European Journal of Neuroscience. 16: 843-9. PMID 12372020 DOI: 10.1046/J.1460-9568.2002.02146.X  0.369
2002 Michelmore S, Croskery K, Nozulak J, Hoyer D, Longato R, Weber A, Bouhelal R, Feuerbach D. Study of the calcium dynamics of the human alpha4beta2, alpha3beta4 and alpha1beta1gammadelta nicotinic acetylcholine receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 366: 235-45. PMID 12172706 DOI: 10.1007/S00210-002-0589-Z  0.453
2002 Lin X, Nunn C, Hoyer D, Rivier J, Peter RE. Identification and characterization of a type five-like somatostatin receptor in goldfish pituitary. Molecular and Cellular Endocrinology. 189: 105-16. PMID 12039069 DOI: 10.1016/S0303-7207(01)00745-6  0.473
2002 Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D. Drug design at peptide receptors: somatostatin receptor ligands. Journal of Molecular Neuroscience : Mn. 18: 15-27. PMID 11931345 DOI: 10.1385/Jmn:18:1-2:15  0.474
2002 Hannon JP, Petrucci C, Fehlmann D, Viollet C, Epelbaum J, Hoyer D. Somatostatin sst2 receptor knock-out mice: Localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography Neuropharmacology. 42: 396-413. PMID 11897118 DOI: 10.1016/S0028-3908(01)00186-1  0.492
2002 Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology, Biochemistry, and Behavior. 71: 533-54. PMID 11888546 DOI: 10.1016/S0091-3057(01)00746-8  0.439
2002 Nunn C, Feuerbach D, Lin X, Peter R, Hoyer D. Pharmacological characterisation of the goldfish somatostatin sst5 receptor. European Journal of Pharmacology. 436: 173-86. PMID 11858797 DOI: 10.1016/S0014-2999(01)01626-0  0.476
2002 Gobbi M, Gariboldi M, Piwko C, Hoyer D, Sperk G, Vezzani A. Distinct Changes in Peptide YY Binding to, and mRNA Levels of, Y1 and Y2 Receptors in the Rat Hippocampus Associated with Kindling Epileptogenesis Journal of Neurochemistry. 70: 1615-1622. PMID 9523578 DOI: 10.1046/J.1471-4159.1998.70041615.X  0.39
2002 Hannon J, Hoyer D. Serotonin receptors and systems: Endless diversity? Acta Biologica Szegediensis. 46: 1-12.  0.3
2001 Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders Neuropsychopharmacology. 25: 904-914. PMID 11750183 DOI: 10.1016/S0893-133X(01)00285-8  0.466
2001 Hannon JP, Langenegger D, Waser B, Hoyer D, Reubi J. Lack of evidence for cross-competition between vasoactive intestinal peptide and somatostatin at their respective receptors. European Journal of Pharmacology. 426: 165-173. PMID 11527540 DOI: 10.1016/S0014-2999(01)01223-7  0.482
2001 Seebach D, Rueping M, Arvidsson PI, Kimmerlin T, Micuch P, Noti C, Langenegger D, Hoyer D. Linear, peptidase-resistant β 2/β 3-Di- and α/β 3-tetrapeptide derivatives with nanomolar affinities to a human somatostatin receptor Helvetica Chimica Acta. 84: 3503-3510. DOI: 10.1002/1522-2675(20011114)84:11<3503::Aid-Hlca3503>3.0.Co;2-A  0.329
2000 Fehlmann D, Langenegger D, Schuepbach E, Siehler S, Feuerbach D, Hoyer D. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery Journal of Physiology-Paris. 94: 265-281. PMID 11088004 DOI: 10.1016/S0928-4257(00)00208-4  0.469
2000 Bruns C, Shi V, Hoyer D, Schuurman H, Weckbecker G. Somatostatin receptors and the potential use of Sandostatin to interfere with vascular remodelling. European Journal of Endocrinology. 143. PMID 11068933 DOI: 10.1530/Eje.0.143S003  0.307
2000 Stork O, Welzl H, Wolfer D, Schuster T, Mantei N, Stork S, Hoyer D, Lipp HP, Obata K, Schachner M. Recovery of emotional behaviour in neural cell adhesion molecule (NCAM) null mutant mice through transgenic expression of NCAM180 European Journal of Neuroscience. 12: 3291-3306. PMID 10998113 DOI: 10.1046/J.1460-9568.2000.00197.X  0.317
2000 Gazi L, Schoeffter P, Nunn C, Croskery K, Hoyer D, Feuerbach D. Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D4 receptor. Naunyn-Schmiedebergs Archives of Pharmacology. 361: 555-564. PMID 10832611 DOI: 10.1007/S002100000236  0.39
2000 Feuerbach D, Fehlmann D, Nunn C, Siehler S, Langenegger D, Bouhelal R, Seuwen K, Hoyer D. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst5 receptor Neuropharmacology. 39: 1451-1462. PMID 10818261 DOI: 10.1016/S0028-3908(00)00063-0  0.495
2000 Lanneau C, Bluet-Pajot MT, Zizzari P, Csaba Z, Dournaud P, Helboe L, Hoyer D, Pellegrini E, Tannenbaum GS, Epelbaum J, Gardette R. Involvement of the Sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. Endocrinology. 141: 967-79. PMID 10698172 DOI: 10.1210/Endo.141.3.7349  0.386
2000 De Lombaert S, Blanchard L, Stamford LB, Tan J, Wallace EM, Satoh Y, Fitt J, Hoyer D, Simonsbergen D, Moliterni J, Marcopoulos N, Savage P, Chou M, Trapani AJ, Jeng AY. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action Journal of Medicinal Chemistry. 43: 488-504. PMID 10669576 DOI: 10.1021/Jm990507O  0.314
1999 Siehler S, Hoyer D. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity Naunyn-Schmiedeberg's Archives of Pharmacology. 360: 522-532. PMID 10598791 DOI: 10.1007/S002109900144  0.484
1999 Siehler S, Hoyer D. Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity Naunyn-Schmiedeberg's Archives of Pharmacology. 360: 510-521. PMID 10598790 DOI: 10.1007/S002109900143  0.501
1999 Siehler S, Hoyer D. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPγS binding Naunyn-Schmiedeberg's Archives of Pharmacology. 360: 500-509. PMID 10598789 DOI: 10.1007/S002109900142  0.483
1999 Siehler S, Seuwen K, Hoyer D. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies Naunyn-Schmiedeberg's Archives of Pharmacology. 360: 488-499. PMID 10598788 DOI: 10.1007/S002109900141  0.499
1999 Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Langenegger D, Sommer B, Hoyer D, Tricklebank M, Schoeffter P. Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. British Journal of Pharmacology. 128: 613-20. PMID 10516640 DOI: 10.1038/Sj.Bjp.0702849  0.412
1999 Zupanc GK, Siehler S, Jones EM, Seuwen K, Furuta H, Hoyer D, Yano H. Molecular cloning and pharmacological characterization of a somatostatin receptor subtype in the gymnotiform fish Apteronotus albifrons. General and Comparative Endocrinology. 115: 333-45. PMID 10480984 DOI: 10.1006/Gcen.1999.7316  0.466
1999 Stork O, Welzl H, Wotjak CT, Hoyer D, Delling M, Cremer H, Schachner M. Anxiety and increased 5-HT1A receptor response in NCAM null mutant mice. Journal of Neurobiology. 40: 343-55. PMID 10440734 DOI: 10.1002/(Sici)1097-4695(19990905)40:3<343::Aid-Neu6>3.0.Co;2-S  0.389
1999 Markstein R, Matsumoto M, Kohler C, Togashi H, Yoshioka M, Hoyer D. Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampus. Naunyn-Schmiedebergs Archives of Pharmacology. 359: 454-459. PMID 10431755 DOI: 10.1007/Pl00005375  0.433
1999 Criado JR, Li H, Jiang X, Spina M, Huitrón-Reséndiz S, Liapakis G, Calbet M, Siehler S, Henriksen SJ, Koob G, Hoyer D, Sutcliffe JG, Goodman M, de Lecea L. Structural and compositional determinants of cortistatin activity. Journal of Neuroscience Research. 56: 611-9. PMID 10374816 DOI: 10.1002/(Sici)1097-4547(19990615)56:6<611::Aid-Jnr7>3.0.Co;2-G  0.34
1999 Siehler S, Zupanc GK, Seuwen K, Hoyer D. Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features. Neuropharmacology. 38: 449-62. PMID 10219983 DOI: 10.1016/S0028-3908(98)00179-8  0.513
1999 Hoyer D. Clinical exploitation of 5-HT receptor diversity Biochemical Society Transactions. 27. DOI: 10.1042/Bst027A026B  0.422
1998 Hoyer D, Fehlmann D, Langenegger D, Kummer J, Giger R, Mattes H, Probst A, Pfannkuche H-. High Affinity of SDZ HTF‐919 and Related Molecules for Calf and Human Caudate 5‐HT4 Receptors Annals of the New York Academy of Sciences. 861: 267-268. PMID 9928283 DOI: 10.1111/J.1749-6632.1998.Tb10217.X  0.406
1998 Hoyer D, Humphrey PA, Barnard EA. Impact of the human genome project on the principles for classification and nomenclature of 5-HT receptors. Annals of the New York Academy of Sciences. 861: 230-1. PMID 9928260 DOI: 10.1111/J.1749-6632.1998.Tb10194.X  0.387
1998 Kalkman HO, Neumann V, Hoyer D, Tricklebank MD. The role of α2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat British Journal of Pharmacology. 124: 1550-1556. PMID 9723970 DOI: 10.1038/Sj.Bjp.0701975  0.344
1998 Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Bruinvels AT, Geisse S, Sommer B, Hoyer D, Tricklebank M, Schoeffter P. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor. British Journal of Pharmacology. 124: 889-96. PMID 9692773 DOI: 10.1038/Sj.Bjp.0701921  0.374
1998 Tran TA, Mattern RH, Afargan M, Amitay O, Ziv O, Morgan BA, Taylor JE, Hoyer D, Goodman M. Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues. Journal of Medicinal Chemistry. 41: 2679-85. PMID 9667958 DOI: 10.1021/Jm970393L  0.39
1998 Siehler S, Seuwen K, Hoyer D. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors European Journal of Pharmacology. 348: 311-320. PMID 9652348 DOI: 10.1016/S0014-2999(98)00159-9  0.456
1998 Siehler S, Seuwen K, Hoyer D. [125I]Tyr10-cortistatin14 labels all five somatostatin receptors Naunyn-Schmiedeberg's Archives of Pharmacology. 357: 483-489. PMID 9650799 DOI: 10.1007/Pl00005197  0.435
1998 Martin GR, Eglen RM, Hamblin MW, Hoyer D, Yocca F. The structure and signalling properties of 5-HT receptors: an endless diversity? Trends in Pharmacological Sciences. 19: 2-4. PMID 9509891 DOI: 10.1016/S0165-6147(97)01143-7  0.458
1998 Martin GR, Eglen RM, Hoyer D, Hamblin MW, Yocca F. Conference on Advances in Serotonin Receptor Research: Molecular Biology, Signal Transduction, and Therapeutics, San Francisco, California, October 8-10, 1997: Preface Annals of the New York Academy of Sciences. 861: XIII-XIV. DOI: 10.1111/J.1749-6632.1998.Tb10166.X  0.374
1997 Schoeffter P, Bobirnac I, Boddeke E, Hoyer D. Inhibition of cAMP accumulation via recombinant human serotonin 5-HT1A receptors: Considerations on receptor effector coupling across systems Neuropharmacology. 36: 429-437. PMID 9225266 DOI: 10.1016/S0028-3908(97)00043-9  0.492
1997 Hoyer D, Martin G. 5-HT receptor classification and nomenclature: Towards a harmonization with the human genome Neuropharmacology. 36: 419-428. PMID 9225265 DOI: 10.1016/S0028-3908(97)00036-1  0.461
1997 Schloos J, Raulf F, Hoyer D, Bruns C. Identification and pharmacological characterization of somatostatin receptors in rat lung British Journal of Pharmacology. 121: 963-971. PMID 9222554 DOI: 10.1038/Sj.Bjp.0701205  0.406
1997 Hoyer D, Humphrey PPA. Nomenclature and classification of transmitter receptors: An integrated approach Journal of Receptor and Signal Transduction Research. 17: 551-568. PMID 9029515 DOI: 10.3109/10799899709036628  0.4
1997 Piwko C, Thoss VS, Probst A, Hoyer D. The elusive nature of cerebellar somatostatin receptors: Studies in rat, monkey and human cerebellum Journal of Receptor and Signal Transduction Research. 17: 385-405. PMID 9029503  0.358
1996 Thoss VS, Kungel M, Friauf E, Hoyer D. Presence of somatostatin sst2 receptors in the developing rat auditory system. Brain Research. Developmental Brain Research. 97: 269-78. PMID 8997511 DOI: 10.1016/S0165-3806(96)00146-0  0.456
1996 Piwko C, Thoss VS, Samanin R, Hoyer D, Vezzani A. Status of somatostatin receptor messenger RNAs and binding sites in rat brain during kindling epileptogenesis. Neuroscience. 75: 857-868. PMID 8951879 DOI: 10.1016/0306-4522(96)00304-1  0.452
1996 Hartig PR, Hoyer D, Humphrey PP, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. Trends in Pharmacological Sciences. 17: 103-5. PMID 8936345 DOI: 10.1016/0165-6147(96)30002-3  0.446
1996 Piwko C, Thoss VS, Probst A, Hoyer D. Localization and pharmacological characterization of somatostatin recognition sites in the human cerebellum. Neuropharmacology. 35: 713-723. PMID 8887980 DOI: 10.1016/0028-3908(96)84643-0  0.428
1996 Thoss VS, Duc D, Hoyer D. Somatostatin receptors in the developing rat brain European Journal of Pharmacology. 297: 145-155. PMID 8851178 DOI: 10.1016/0014-2999(95)00736-9  0.345
1996 Hoyer D, Martin GR. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behavioural Brain Research. 73: 263-8. PMID 8788515 DOI: 10.1016/0166-4328(96)00109-X  0.422
1996 Bruns C, Raulf F, Hoyer D, Schloos J, Lübbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism-Clinical and Experimental. 45: 17-20. PMID 8769372 DOI: 10.1016/S0026-0495(96)90072-4  0.434
1996 Thoss VS, Piwko C, Hoyer D. Somatostatin receptors in the Rhesus monkey brain: Localization and pharmacological characterization Naunyn-Schmiedeberg's Archives of Pharmacology. 353: 648-660. PMID 8738298 DOI: 10.1007/Bf00167184  0.434
1995 Piwko C, Silke Thoss V, Hoyer D. Localization and pharmacological characterization of somatostatin sst2 sites in the rat cerebellum Naunyn-Schmiedeberg's Archives of Pharmacology. 352: 607-613. PMID 9053731 DOI: 10.1007/BF00171318  0.345
1995 Thoss VS, Ferez J, Duc D, Hoyer D. Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain Neuropharmacology. 34: 1673-1688. PMID 8788965 DOI: 10.1016/0028-3908(95)00135-2  0.368
1995 Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology. 34: 1635-1645. PMID 8788961 DOI: 10.1016/0028-3908(95)00138-7  0.475
1995 Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A, Taylor JE. Classification and nomenclature of somatostatin receptors. Trends in Pharmacological Sciences. 16: 86-8. PMID 7792934 DOI: 10.1016/S0165-6147(00)88988-9  0.454
1995 Schoeffter P, Pérez J, Langenegger D, Schüpbach E, Bobirnac I, Lübbert H, Bruns C, Hoyer D. Characterization and distribution of somatostatin SS-1 and SRIF-1 binding sites in rat brain: identity with SSTR-2 receptors. European Journal of Pharmacology. 289: 163-73. PMID 7781707 DOI: 10.1016/0922-4106(95)90180-9  0.447
1995 Hoyer D, Pérez J, Schoeffter P, Langenegger D, Schüpbach E, Kaupmann K, Lübbert H, Bruns C, Reubi JC. Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors. European Journal of Pharmacology. 289: 151-61. PMID 7781706 DOI: 10.1016/0922-4106(95)90179-5  0.475
1995 Pérez J, Hoyer D. Co-expression of somatostatin SSTR-3 and SSTR-4 receptor messenger RNAs in the rat brain Neuroscience. 64: 241-253. PMID 7708209 DOI: 10.1016/0306-4522(94)00364-B  0.324
1995 Pérez J, Vezzani A, Civenni G, Tutka P, Rizzi M, Schüpbach E, Hoyer D. Functional effects of D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. Neuroscience. 65: 1087-97. PMID 7617164 DOI: 10.1016/0306-4522(94)00535-D  0.432
1995 Hoyer D, Perez J, Thoss VS, Piwko C, Probst A, Vezzani A. Distribution and function of central somatostatin (SRIF) receptors Pharmacological Research. 31: 164. DOI: 10.1016/1043-6618(95)86917-4  0.395
1995 Schoeffter P, Bruns C, Kaupmann C, Lübbert H, Raulf F, Hoyer D. Somatostatin receptors in guinea-pig ileum are of the SST2 subtype Pharmacological Research. 31: 103. DOI: 10.1016/1043-6618(95)86672-8  0.461
1994 Pérez J, Rigo M, Kaupmann K, Bruns C, Yasuda K, Bell GI, Lübbert H, Hoyer D. Localization of somatostatin (SRIF) SSTR-1, SSTR-2 and SSTR-3 receptor mRNA in rat brain by in situ hybridization. Naunyn-Schmiedeberg's Archives of Pharmacology. 349: 145-60. PMID 8170498 DOI: 10.1007/Bf00169831  0.359
1994 Bruinvels AT, Landwehrmeyer B, Probst A, Palacios JM, Hoyer D. A comparative autoradiographic study of 5-HT1D binding sites in human and guinea-pig brain using different radioligands. Brain Research. Molecular Brain Research. 21: 19-29. PMID 8164519 DOI: 10.1016/0169-328X(94)90374-3  0.418
1994 Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, Hoyer D, Palacios JM. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 33: 367-86. PMID 7984275 DOI: 10.1016/0028-3908(94)90067-1  0.442
1994 Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lübbert H. Molecular pharmacology of somatostatin-receptor subtypes. Annals of the New York Academy of Sciences. 733: 138-46. PMID 7978861 DOI: 10.1111/J.1749-6632.1994.Tb17263.X  0.442
1994 Hoyer D, Lübbert H, Bruns C. Molecular pharmacology of somatostatin receptors Naunyn-Schmiedeberg's Archives of Pharmacology. 350: 441-453. PMID 7870182 DOI: 10.1007/Bf00173012  0.467
1994 Rocha B, Rigo M, Scala GD, Sandner G, Hoyer D. Chromic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels European Journal of Pharmacology. 262: 125-131. PMID 7813563 DOI: 10.1016/0014-2999(94)90035-3  0.409
1994 Raulf F, Pérez J, Hoyer D, Burns C. Differential expression of riruns five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue Digestion. 55: 46-53. PMID 7698537 DOI: 10.1159/000201201  0.441
1994 Hoyer D, Schoeffter P, Kaupmann K, Seuwen K, Langenegger D, Reubi J, Lübbert H, Bruns C. Pharmacological identity between somatostatin SS-1SS-2 sites and SSTR-2SSTR-1 receptors, respectively Neuropeptides. 26: 24. DOI: 10.1016/0143-4179(94)90193-7  0.441
1994 Hoyer D, Bruns C, Perez J, Schoeffter P, Seuwen K, Kaupmann K, Raulf F, Lübbert H. Molecular pharmacology and biology of somatostatin (SRIF) receptors Neuropeptides. 26: 21-22. DOI: 10.1016/0143-4179(94)90184-8  0.432
1993 Bruinvels AT, Palacios JM, Hoyer D. 5-hydroxytryptamine1 recognition sites in rat brain: heterogeneity of non-5-hydroxytryptamine1A/1C binding sites revealed by quantitative receptor autoradiography. Neuroscience. 53: 465-73. PMID 8492913 DOI: 10.1016/0306-4522(93)90210-7  0.387
1993 Boddeke HW, Hoffman BJ, Palacios JM, Knot H, Hoyer D. Characterization of functional responses in A9 cells transfected with cloned rat 5-HT1C receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 347: 119-24. PMID 8474532 DOI: 10.1007/Bf00169255  0.363
1993 Kaupmann K, Bruns C, Hoyer D, Seuwen K, Lübbert H. Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain. Febs Letters. 331: 53-9. PMID 8405411 DOI: 10.1016/0014-5793(93)80296-7  0.433
1993 Schoeffter P, Fozard JR, Stoll A, Siegl H, Seiler MP, Hoyer D. SDZ 216-525, a selective and potent 5-HT1A receptor antagonist. European Journal of Pharmacology. 244: 251-257. PMID 8384569 DOI: 10.1016/0922-4106(93)90150-8  0.499
1993 Humphrey PPA, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors Trends in Pharmacological Sciences. 14: 233-236. PMID 8372403 DOI: 10.1016/0165-6147(93)90016-D  0.37
1993 Bruinvels AT, Palacios JM, Hoyer D. Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn-Schmiedeberg's Archives of Pharmacology. 347: 569-82. PMID 8361548 DOI: 10.1007/Bf00166939  0.36
1993 Bax WA, Bruinvels AT, Suylen Rv, Saxena PR, Hoyer D. Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn-Schmiedebergs Archives of Pharmacology. 348: 403-410. PMID 8277976 DOI: 10.1007/Bf00171340  0.313
1993 Rocha B, Scala GD, Rigo M, Hoyer D, Sandner G. Effect of 5,7-dihydroxytryptamine lesion on mianserin-induced conditioned place aversion and on 5-hydroxytryptamine1C receptors in the rat brain Neuroscience. 56: 687-693. PMID 8255427 DOI: 10.1016/0306-4522(93)90365-M  0.442
1993 Hoyer D, Boddeke HWGM. Partial agonists, full agonists, antagonists: dilemmas of definition Trends in Pharmacological Sciences. 14: 270-275. PMID 8105597 DOI: 10.1016/0165-6147(93)90129-8  0.457
1993 Sharp T, McQuade R, Fozard JR, Hoyer D. The novel 5‐HT1A receptor antagonist, SDZ 216–525, decreases 5‐HT release in rat hippocampus in vivo British Journal of Pharmacology. 109: 699-702. PMID 8102935 DOI: 10.1111/J.1476-5381.1993.Tb13630.X  0.447
1993 Boddeke HW, Hoffman BJ, Palacios JM, Hoyer D. Calcineurin inhibits desensitization of cloned rat 5-HT1C receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 348: 221-4. PMID 7694158 DOI: 10.1007/Bf00169147  0.415
1993 Bruinvels AT, Landwehrmeyer B, Moskowitz MA, Hoyer D. Evidence for the presence of 5-HT1B receptor messenger RNA in neurons of the rat trigeminal ganglia. European Journal of Pharmacology. 227: 357-9. PMID 1473558 DOI: 10.1016/0922-4106(92)90017-P  0.444
1992 Boddeke H, Fargin A, Raymond JR, Schoeffter P, Hoyer D. Agonist Antagonist Interactions With Cloned Human 5-Ht1A Receptors - Variations In Intrinsic Activity Studied In Transfected Hela-Cells Naunyn-Schmiedebergs Archives of Pharmacology. 345: 257-263. PMID 1535691 DOI: 10.1007/Bf00168684  0.47
1992 Foguet M, Hoyer D, Pardo LA, Parekh A, Kluxen FW, Kalkman HO, Stühmer W, Lübbert H. Cloning and functional characterization of the rat stomach fundus serotonin receptor. The Embo Journal. 11: 3481-7. PMID 1505525 DOI: 10.1002/J.1460-2075.1992.Tb05427.X  0.444
1992 Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM. "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain. Naunyn-Schmiedeberg's Archives of Pharmacology. 346: 249-54. PMID 1407010 DOI: 10.1007/Bf00173536  0.383
1992 Bruinvels AT, Lery H, Nozulak J, Palacios JM, Hoyer D. 5-HT1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes. Naunyn-Schmiedeberg's Archives of Pharmacology. 346: 243-8. PMID 1407009 DOI: 10.1007/Bf00173535  0.381
1992 Palacios JM, Waeber C, Bruinvels AT, Hoyer D. Direct visualization of serotonin1D receptors in the human brain using a new iodinated radioligand. Brain Research. Molecular Brain Research. 13: 175-8. PMID 1315914 DOI: 10.1016/0169-328X(92)90060-O  0.427
1992 Hoyer D. 5-Hydroxytryptamine (5-HT) receptor superfamilies Neurochemistry International. 21. DOI: 10.1016/0197-0186(92)91843-L  0.436
1991 Sahin-Erdemli I, Schoeffter P, Hoyer D. Competitive antagonism by recognised 5-HT2 receptor antagonists at 5-HT1C receptors in pig choroid plexus Naunyn-Schmiedeberg's Archives of Pharmacology. 344: 137-142. PMID 1944609 DOI: 10.1007/Bf00167210  0.492
1991 Hoyer D, Schoeffter P. 5-HT receptors: Subtypes and second messengers Journal of Receptors and Signal Transduction. 11: 197-214. PMID 1886080 DOI: 10.3109/10799899109066399  0.365
1991 Sahin‐Erdemli I, Hoyer D, Stoll A, Seiler MP, Schoeffter P. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of guinea-pig isolated iliac artery. British Journal of Pharmacology. 102: 386-390. PMID 1849768 DOI: 10.1111/J.1476-5381.1991.Tb12183.X  0.405
1991 Bruinvels AT, Landwehrmeyer B, Waeber C, Palacios JM, Hoyer D. Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand. European Journal of Pharmacology. 202: 89-91. PMID 1786802 DOI: 10.1016/0014-2999(91)90257-Q  0.32
1991 Schoeffter P, Hoyer D. Interaction of the α-adrenoceptor agonist oxymetazoline with serotonin 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors European Journal of Pharmacology. 196: 213-216. PMID 1678720 DOI: 10.1016/0014-2999(91)90432-P  0.512
1991 Palacios J, Waeber C, Mengod G, Hoyer D. Autoradiography of 5-HT receptors: A critical appraisal Neurochemistry International. 18: 17-25. DOI: 10.1016/0197-0186(91)90030-H  0.44
1991 Hoyer D. Receptor biochemistry and methodology volume 15: Serotonin receptor subtypes Trends in Pharmacological Sciences. 12: 316. DOI: 10.1016/0165-6147(91)90585-G  0.48
1990 Palacios JM, Waeber C, Hoyer D, Mengod G. Distribution of serotonin receptors. Annals of the New York Academy of Sciences. 600: 36-52. PMID 2252320 DOI: 10.1111/J.1749-6632.1990.Tb16871.X  0.44
1990 Hoyer D, Schoeffter P, Waeber C, Palacios JM. Serotonin 5-HT1D receptors. Annals of the New York Academy of Sciences. 600: 168-81; discussion 1. PMID 2252308 DOI: 10.1111/J.1749-6632.1990.Tb16880.X  0.52
1990 Waeber C, Schoeffter P, Hoyer D, Palacios JM. The serotonin 5-HT1D receptor: a progress review. Neurochemical Research. 15: 567-82. PMID 2215849 DOI: 10.1007/Bf00973745  0.487
1990 Jones CR, Palacios JM, Hoyer D, Bühler FR. Receptor modification in the brains of spontaneously hypertensive and Wistar-Kyoto rats: regionally specific and selective increase in cerebellar beta 2-adrenoceptors. British Journal of Clinical Pharmacology. 30: 174S-177S. PMID 2176525 DOI: 10.1111/J.1365-2125.1990.Tb05498.X  0.38
1990 Waeber C, Hoyer D, Palacios JM. Similar distribution of [125I]sarafotoxin-6b and [125I]endothelin-1, -2, -3 binding sites in the human kidney. European Journal of Pharmacology. 176: 233-6. PMID 2155801 DOI: 10.1016/0014-2999(90)90534-D  0.326
1990 Schoeffter P, Hoyer D. 5-hydroxytryptamine (5-HT)-induced endothelium-dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 5-HT(1D) receptor subtype Journal of Pharmacology and Experimental Therapeutics. 252: 387-395. PMID 2137176  0.327
1990 Hoyer D, Jones CR, Ford W, Palacios JM. Subtypes of alpha 1-adrenoceptors in hippocampus of pigs, guinea-pigs, calves and humans: regional differences. European Journal of Pharmacology. 188: 9-16. PMID 1968395 DOI: 10.1016/0922-4106(90)90242-P  0.342
1989 Waeber C, Hoyer D, Palacios JM. 5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930. Neuroscience. 31: 393-400. PMID 2797443 DOI: 10.1016/0306-4522(89)90382-5  0.419
1989 Schlicker E, Fink K, Göthert M, Hoyer D, Molderings G, Roschke I, Schoeffter P. The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype. Naunyn-Schmiedebergs Archives of Pharmacology. 340: 45-51. PMID 2797214 DOI: 10.1007/Bf00169206  0.5
1989 Schoeffter P, Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn-Schmiedeberg's Archives of Pharmacology. 339: 675-683. PMID 2770889 DOI: 10.1007/Bf00168661  0.516
1989 Hoyer D, Waeber C, Schoeffter P, Palacios JM, Dravid A. 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization. Naunyn-Schmiedeberg's Archives of Pharmacology. 339: 252-8. PMID 2725702 DOI: 10.1007/Bf00173573  0.434
1989 Hoyer D, Middlemiss DN. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain Trends in Pharmacological Sciences. 10: 130-132. PMID 2665245 DOI: 10.1016/0165-6147(89)90159-4  0.325
1989 Hoyer D, Gozlan H, Bolanos F, Schechter LE, Hamon M. Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact? European Journal of Pharmacology. 171: 137-9. PMID 2612568 DOI: 10.1016/0014-2999(89)90438-X  0.355
1989 Hoyer D, Waeber C, Karpf A, Neijt H, Palacios JM. [3H]ICS 205-930 labels 5-HT3 recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion. Naunyn-Schmiedeberg's Archives of Pharmacology. 340: 396-402. PMID 2586633 DOI: 10.1007/Bf00167040  0.405
1989 Schoeffter P, Hoyer D. 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity: Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some β-adrenoceptor antagonists Naunyn-Schmiedeberg's Archives of Pharmacology. 340: 285-292. PMID 2572975 DOI: 10.1007/Bf00168512  0.497
1989 Schoeffter P, Hoyer D. Is the sumatripan (GR 43175)-induced endothelium-dependent relaxation of pig coronary arteries mediated by 5-HT1D receptors? European Journal of Pharmacology. 166: 117-119. PMID 2553426 DOI: 10.1016/0014-2999(89)90692-4  0.38
1989 Schoeffter P, Hoyer D. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors Naunyn-Schmiedeberg's Archives of Pharmacology. 340: 135-138. PMID 2552330 DOI: 10.1007/Bf00169219  0.519
1989 Waeber C, Schoeffter P, Palacios JM, Hoyer D. 5-HT1D receptors in guinea-pig and pigeon brain. Radioligand binding and biochemical studies. Naunyn-Schmiedeberg's Archives of Pharmacology. 340: 479-85. PMID 2533324 DOI: 10.1007/Bf00260601  0.443
1989 Hoyer D, Waeber C, Palacios JM. [125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans. Journal of Cardiovascular Pharmacology. 13: S162-5. PMID 2473297 DOI: 10.1097/00005344-198900135-00044  0.313
1989 Hoyer D, Schoeffter P, Gray JA. A comparison of the interactions of dihydroergotamine, ergotamine and GR 43175 with 5-HT1 receptor subtypes Cephalalgia. 9: 340-341. DOI: 10.1177/0333102489009S10181  0.434
1988 Neijt HC, Karpf A, Schoeffter P, Engel G, Hoyer D. Characterisation of 5-HT3 Recognition Sites in Membranes of NG 108-15 Neuroblastoma-Glioma Cells With [3H]ICS 205-930 Naunyn-Schmiedebergs Archives of Pharmacology. 337: 493-499. PMID 3412489 DOI: 10.1007/Bf00182721  0.42
1988 Hoyer D, Karpf A. [125I]SCH 23982, a 'selective' D-1 receptor antagonist, labels with high affinity 5-HT1C sites in pig choroid plexus European Journal of Pharmacology. 150: 181-184. PMID 3402537 DOI: 10.1016/0014-2999(88)90766-2  0.477
1988 Waeber C, Dietl MM, Hoyer D, Probst A, Palacios JM. Visualization of a novel serotonin recognition site (5-HT1D) in the human brain by autoradiography. Neuroscience Letters. 88: 11-6. PMID 3399126 DOI: 10.1016/0304-3940(88)90307-2  0.384
1988 Hoyer D, Schoeffter P. 5-HT1D receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in calf substantia nigra European Journal of Pharmacology. 147: 145-147. PMID 3371410 DOI: 10.1016/0014-2999(88)90645-0  0.389
1988 Hoyer D, Neijt HC. Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding Molecular Pharmacology. 33: 303-309. PMID 3352595  0.308
1988 Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites Journal of Receptors and Signal Transduction. 8: 59-81. PMID 3290473 DOI: 10.3109/10799898809048978  0.318
1988 Schoeffter P, Waeber C, Palacios JM, Hoyer D. The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra. Naunyn-Schmiedeberg's Archives of Pharmacology. 337: 602-8. PMID 3216894 DOI: 10.1007/Bf00175784  0.449
1988 Schoeffter P, Hoyer D. Centrally acting hypotensive agents with affinity for 5‐HT1A binding sites inhibit forskolin‐stimulated adenylate cyclase activity in calf hippocampus British Journal of Pharmacology. 95: 975-985. PMID 3207999 DOI: 10.1111/J.1476-5381.1988.Tb11728.X  0.406
1988 Waeber C, Dixon K, Hoyer D, Palacios JM. Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS. European Journal of Pharmacology. 151: 351-2. PMID 3169128 DOI: 10.1016/0014-2999(88)90825-4  0.409
1988 Hoyer D. Molecular pharmacology and biology of 5-HT1C receptors Trends in Pharmacological Sciences. 9: 89-94. PMID 3072739 DOI: 10.1016/0165-6147(88)90174-5  0.494
1988 Waeber C, Schoeffter P, Palacios JM, Hoyer D. Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn-Schmiedeberg's Archives of Pharmacology. 337: 595-601. PMID 2975354 DOI: 10.1007/Bf00175783  0.393
1988 Hoyer D, Waeber C, Pazos A, Probst A, Palacios JM. Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites. Neuroscience Letters. 85: 357-62. PMID 2966310 DOI: 10.1016/0304-3940(88)90592-7  0.394
1988 Doods HN, Boddeke HWGM, Kalkman HO, Hoyer D, Mathy M-, Zwieten PAV. Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R28935, and urapidil. Journal of Cardiovascular Pharmacology. 11: 432-437. PMID 2453746 DOI: 10.1097/00005344-198804000-00008  0.373
1987 Hoyer D, Neijt HC. Identification of serotonin 5-HT3 recognition sites by radioligand binding in NG108-15 neuroblastoma-glioma cells European Journal of Pharmacology. 143: 291-292. PMID 3691658 DOI: 10.1016/0014-2999(87)90547-4  0.391
1987 Hoyer D, Vos P, Closse A, Pazos A, Palacios JM, Davies H. [3H]ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes. Naunyn-Schmiedeberg's Archives of Pharmacology. 335: 226-30. PMID 2884572 DOI: 10.1007/Bf00172788  0.411
1987 Palacios JM, Hoyer D, Cortés R. α1-adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates Brain Research. 419: 65-75. PMID 2823969 DOI: 10.1016/0006-8993(87)90569-5  0.315
1987 Hoyer D, Vos P, Closse A, Palacios JM, Engel G, Davies H. [3H]ketanserin labels serotonin 5-HT2 and alpha 1-adrenergic receptors in human brain cortex. Journal of Cardiovascular Pharmacology. 10. DOI: 10.1097/00005344-198700103-00012  0.427
1986 Kalkman HO, Engel G, Hoyer D. Inhibition of 5-carboxamidotryptamine-induced relaxation of guinea-pig ileum correlates with [125I]LSD binding European Journal of Pharmacology. 129: 139-145. PMID 3770071 DOI: 10.1016/0014-2999(86)90345-6  0.444
1986 Hoyer D, Srivatsa S, Pazos A, Engel G, Palacios JM. [125I]LSD labels 5-HT1C recognition sites in pig choroid plexus membranes. Comparison with [3H]mesulergine and [3H]5-HT binding. Neuroscience Letters. 69: 269-74. PMID 3763057 DOI: 10.1016/0304-3940(86)90492-1  0.345
1986 Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Research. 376: 85-96. PMID 3719375 DOI: 10.1016/0006-8993(86)90902-9  0.487
1986 Markstein R, Hoyer D, Engel G. 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus Naunyn-Schmiedeberg's Archives of Pharmacology. 333: 335-341. PMID 2945992 DOI: 10.1007/Bf00500006  0.469
1986 Doyle VM, Creba JA, Rüegg UT, Hoyer D. Serotonin increases the production of inositol phosphates and mobilises calcium via the 5-HT2 receptor in A7r5 smooth muscle cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 333: 98-103. PMID 2944005 DOI: 10.1007/Bf00506510  0.395
1986 Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Research. 376: 97-107. PMID 2941113 DOI: 10.1016/0006-8993(86)90903-0  0.47
1986 Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedebergs Archives of Pharmacology. 332: 1-7. PMID 2936965 DOI: 10.1007/Bf00633189  0.442
1986 Hoyer D. Implications of stereoselectivity in radioligand binding studies Trends in Pharmacological Sciences. 7: 227-230. DOI: 10.1016/0165-6147(86)90328-7  0.382
1985 Hoyer D, Engel G, Kalkman HO. Characterization of the 5-HTIB recognition site in rat brain: Binding studies with (-)[125I]Iodocyanopindolol European Journal of Pharmacology. 118: 1-12. PMID 3002805 DOI: 10.1016/0014-2999(85)90657-0  0.409
1985 Hoyer D, Engel G, Kalkman HO. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: Radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]Ketanserin European Journal of Pharmacology. 118: 13-23. PMID 2935410 DOI: 10.1016/0014-2999(85)90658-2  0.4
1984 Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. European Journal of Pharmacology. 106: 539-46. PMID 6519175 DOI: 10.1016/0014-2999(84)90057-8  0.386
1984 Pazos A, Hoyer D, Palacios JM. Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. European Journal of Pharmacology. 106: 531-8. PMID 6519174 DOI: 10.1016/0014-2999(84)90056-6  0.454
1984 Hoyer D, Reynolds EE, Molinoff PB. Agonist-induced changes in the properties of beta-adrenergic receptors on intact S49 lymphoma cells. Time-dependent changes in the affinity of the receptor for agonists. Molecular Pharmacology. 25: 209-18. PMID 6142414  0.363
1982 Hoyer D, Engel G, Berthold R. Binding characteristics of (+)-, (±)- and (-)-[125Iodo] cyanopindolol to guinea-pig left ventricle membranes Naunyn-Schmiedeberg's Archives of Pharmacology. 318: 319-329. PMID 6281670 DOI: 10.1007/Bf00501172  0.36
1982 Paietta E, Hoyer D, Engel G, Schwarzmeier JD. Non-specific uptake of the radioligand 125I-IHYP by intact human lymphocytes: Reversal of the uptake process Molecular and Cellular Endocrinology. 25: 267-276. PMID 6279459 DOI: 10.1016/0303-7207(82)90083-1  0.365
1982 Engel G, Hoyer D. [125Iodo]BE 2254, a new radioligand for α1-adrenoceptors Journal of Cardiovascular Pharmacology. 4: S25-S29. PMID 6175839 DOI: 10.1097/00005344-198200041-00006  0.322
1981 Engel G, Hoyer D. [125I]BE 2254, a new high affinity radioligand for α1-adrenoceptors European Journal of Pharmacology. 73: 221-224. PMID 6273186 DOI: 10.1016/0014-2999(81)90095-9  0.312
1981 Engel G, Hoyer D, Berthold R, Wagner H. (±)[125Iodo]cyanopindolol, a new ligand for β-adrenoceptors: Identification and quantitation of subclasses of β-adrenoceptors in guinea pig Naunyn-Schmiedeberg's Archives of Pharmacology. 317: 277-285. PMID 6119625 DOI: 10.1007/Bf00501307  0.333
Show low-probability matches.